Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00790023 · ClinicalTrials.gov registry record · Phase 3
Clinical Trial to Assess the Efficacy and Safety of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol for the Treatment of Seasonal Allergic Rhinitis
A Phase 3 study, sponsored by Sumitomo Pharma America.
- Completed
- Registry status
- Phase 3
- Development phase
- 707
- Enrollment target
NCT00790023 is a Phase 3 study that has completed, run by Sumitomo Pharma America. The registered enrollment target is 707 participants.
The verdict
NCT00790023, a Phase 3 study, has completed, sponsored by Sumitomo Pharma America.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 707 participants
- Enrollment target
Study Summary
To demonstrate the efficacy of ciclesonide HFA applied as a nasal aerosol (160 μg and 80 μg) once daily compared to placebo in subjects with SAR.
Interventions
- DRUG Placebo
- DRUG 80 mcg Ciclesonide
- DRUG 160 mcg Ciclesonide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 707 participants |
| Start Date | 2008-11 |
| Est. Completion | 2009-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00790023
The ClinicalTrials.gov registry entry for NCT00790023 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 707 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sumitomo Pharma America, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00790023 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00790023 about?
NCT00790023 is a clinical study titled "Clinical Trial to Assess the Efficacy and Safety of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol for the Treatment of Seasonal Allergic Rhinitis". To demonstrate the efficacy of ciclesonide HFA applied as a nasal aerosol (160 μg and 80 μg) once daily compared to placebo in subjects with SAR.
What is the current status of trial NCT00790023?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 707 participants. The study started on 2008-11. Estimated completion is 2009-02.
What interventions are being tested in trial NCT00790023?
The interventions under investigation include: Placebo (DRUG), 80 mcg Ciclesonide (DRUG), 160 mcg Ciclesonide (DRUG).
Who is sponsoring clinical trial NCT00790023?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.